Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies

    • 16:15 - 17:15
    • 9/13/2021
    • Location: Industry Symposium Auditorium via Industry Hub
    • Not for CME Credit
    • Type: Industry Supported Symposium
    • Track: N.A.
    • +

      IS14.01 - Disease Landscape Overview

      16:15 - 16:30  |  Presenter: Luis Paz-Ares

      • Abstract

      No abstract available for this presentation

    • +

      IS14.02 - Pathobiology and Molecular Profile of ADC Targets in NSCLC

      16:30 - 16:40  |  Presenter: Corey Langer

      • Abstract

      No abstract available for this presentation

    • +

      IS14.03 - ADCs Targeting the HER Family and Clinical Data in NSCLC

      16:40 - 16:50  |  Presenter: Keunchil Park

      • Abstract

      No abstract available for this presentation

    • +

      IS14.04 - Emerging ADC Targets and Clinical Data in NSCLC

      16:50 - 17:00  |  Presenter: Marina Chiara Garassino

      • Abstract

      No abstract available for this presentation

    • +

      IS14.05 - Faculty Panel: Live Q&A

      17:00 - 17:15

      • Abstract

      No abstract available for this presentation

  • +

    MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?

    • 17:30 - 18:30
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

      17:30 - 17:35  |  Presenter: Shengxiang (Harry) Ren

      • Abstract

      Loading...

    • +

      MA13.02 - Phase II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Recurrent Non-Small Cell Lung Cancer

      17:35 - 17:40  |  Presenter: Sonam Puri

      • Abstract

      Loading...

    • +

      MA13.03 - Combination of Bevacizumab + Atezolizumab (A) Who Progressed On A In Pretreated NSCLC Patients: An Open-Label, Two-Stage, Phase II Trial

      17:40 - 17:45  |  Presenter: Jiyun Lee

      • Abstract

      Loading...

    • +

      MA13.04 - Discussant

      17:45 - 17:55  |  Presenter: Alessandra Curioni-Fontecedro

      • Abstract

      No abstract available for this presentation

    • +

      MA13.05 - Prognostic Impact of Immune Related Adverse Events in Advanced Non-Small Cell Lung Cancer Patients with ICIs Treatment

      17:55 - 18:00  |  Presenter: Huijuan wang

      • Abstract

      Loading...

    • +

      MA13.06 - Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy

      18:00 - 18:05  |  Presenter: Benedict James Girling

      • Abstract

      Loading...

    • +

      MA13.07 - GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC

      18:05 - 18:10  |  Presenter: Caicun Zhou

      • Abstract

      Loading...

    • +

      MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

      18:10 - 18:15  |  Presenter: Jie Wang

      • Abstract

      Loading...

    • +

      MA13.09 - Discussant

      18:15 - 18:30  |  Presenter: Keunchil Park

      • Abstract

      No abstract available for this presentation

  • +

    OA18 - Real World Data in a Modern World

    • 17:30 - 18:30
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Global Health
    • +

      OA18.01 - Lung Cancer in Vietnam

      17:30 - 17:40  |  Presenter: Sang Nguyen

      • Abstract

      Loading...

    • +

      OA18.02 - Canprim Beyond Oncology Into Primary Care Cancer Distress Follow-up Study Among Outpatients

      17:40 - 17:50  |  Presenter: Aissa Gabriela Suciu

      • Abstract

      Loading...

    • +

      OA18.03 - LUNGCOVID: SARS-CoV-2 Infection in Patients With Thoracic Tumors - Multicenter Observational Study in Portugal

      17:50 - 18:00  |  Presenter: Denise Magalhães

      • Abstract

      Loading...

    • +

      OA18.04 - Discussant

      18:00 - 18:10  |  Presenter: Bill Mayfield

      • Abstract

      No abstract available for this presentation

    • +

      OA18.05 - Live Discussion with Speakers

      18:10 - 18:30

      • Abstract

      No abstract available for this presentation

  • +

    OA19 - Screening and Early Detection: State of the Art

    • 17:30 - 18:30
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Screening and Early Detection
    • +

      OA19.01 - Prospective Study of Lung Cancer Screening Criteria: USPSTF2013 vs PLCOm2012 – International Lung Screening Trial (ILST) Results 

      17:30 - 17:40  |  Presenter: Martin C Tammemagi

      • Abstract

      Loading...

    • +

      OA19.02 - The UKLS Trial Outcome Results: Lung Cancer Mortality Reduction by LDCT Screening Confirmed in an International Meta-Analysis

      17:40 - 17:50  |  Presenter: John K Field

      • Abstract

      Loading...

    • +

      OA19.03 - Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-Dose CT Screening

      17:50 - 18:00  |  Presenter: Yeon Wook Kim

      • Abstract

      Loading...

    • +

      OA19.04 - Potential Clinical and Economic Impact of Missed Lung Nodules – A Claims Database Analysis

      18:00 - 18:10  |  Presenter: Fernando J Suarez Saiz

      • Abstract

      Loading...

    • +

      OA19.05 - Discussant

      18:10 - 18:20  |  Presenter: Annette Maree McWilliams

      • Abstract

      No abstract available for this presentation

    • +

      OA19.06 - Live Discussion with Speakers

      18:20 - 18:30

      • Abstract

      No abstract available for this presentation

  • +

    MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC

    • 18:45 - 19:45
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      MA14.01 - Distribution and Detectability of EGFR Exon 20 Insertion Variants in Non–Small Cell Lung Cancer

      18:45 - 18:50  |  Presenter: Sai-Hong I. Ou

      • Abstract

      Loading...

    • +

      MA14.02 - RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study

      18:50 - 18:55  |  Presenter: Fernando Lopez-Rios

      • Abstract

      Loading...

    • +

      MA14.03 - Genomic Profiles and Potential Determinants of Response and Resistance in KRAS p.G12C-mutated NSCLC Treated With Sotorasib

      18:55 - 19:00  |  Presenter: Ferdinandos Skoulidis

      • Abstract

      Loading...

    • +

      MA14.04 - Discussant

      19:00 - 19:15  |  Presenter: Umberto Mallapelle

      • Abstract

      No abstract available for this presentation

    • +

      MA14.05 - Clinicopathologic and Genomic Significances of the Amount of High-Grade Histologic Components in Lung Adenocarcinoma

      19:15 - 19:20  |  Presenter: Bokyung Ahn

      • Abstract

      Loading...

    • +

      MA14.06 - High Tumor Mutation Burden Predicts Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinoma Treated With Targeted Therapy

      19:20 - 19:25  |  Presenter: Seung Hyeun Lee

      • Abstract

      Loading...

    • +

      MA14.07 - EGFR-Mutant NSCLC With de novo or Acquired Squamous Histology: Molecular Features and Clinical Outcomes

      19:25 - 19:30  |  Presenter: Catherine Belle Meador

      • Abstract

      Loading...

    • +

      MA14.08 - Discussant

      19:30 - 19:45  |  Presenter: Lukas Bubendorf

      • Abstract

      No abstract available for this presentation

  • +

    MA15 - Real World Factors Affecting Lung Cancer Outcomes

    • 18:45 - 19:45
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Health Services Research/Health Economics
    • +

      MA15.01 - Machine Learning for Prediction of Survival and Risk of Mortality in Patients with Lung Cancer Undergoing Resection

      18:45 - 18:50  |  Presenter: Renata Matheus Faccioli

      • Abstract

      Loading...

    • +

      MA15.02 - Association of Healthcare System Resources With Lung Cancer Screening Utilization

      18:50 - 18:55  |  Presenter: Jennifer A. Lewis

      • Abstract

      Loading...

    • +

      MA15.03 - Social Factors Influencing the Length of Stay in Hospital After Anatomical Resection

      18:55 - 19:00  |  Presenter: Miriam Patella

      • Abstract

      Loading...

    • +

      MA15.04 - Discussant

      19:00 - 19:15  |  Presenter: Dan Raz

      • Abstract

      No abstract available for this presentation

    • +

      MA15.05 - Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients in The U.S. ALCHEMIST Study (Alliance)

      19:15 - 19:20  |  Presenter: Kenneth L Kehl

      • Abstract

      Loading...

    • +

      MA15.06 - Real World Trends in Treatment Patterns for Patients With Advanced NSCLC: Comparing Changes Between Younger and Older Adults

      19:20 - 19:25  |  Presenter: Bonnie Leung

      • Abstract

      Loading...

    • +

      MA15.07 - Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-small Cell Lung Cancer Patients ≥75 Years Old of Age

      19:25 - 19:30  |  Presenter: Shinkichi Takamori

      • Abstract

      Loading...

    • +

      MA15.08 - Discussant

      19:30 - 19:45  |  Presenter: Andrew G. Robinson

      • Abstract

      No abstract available for this presentation

  • +

    OA20 - Exploring Treatment Modalities and Tools in Locally Advanced NSCLC

    • 18:45 - 19:45
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Locally Advanced Non-Small Cell Lung Cancer
    • +

      OA20.01 - Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study

      18:45 - 18:53  |  Presenter: Mariano Provencio

      • Abstract

      Loading...

    • +

      OA20.02 - Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy

      18:53 - 19:01  |  Presenter: Atocha Romero

      • Abstract

      Loading...

    • +

      OA20.03 - Discussant

      19:01 - 19:09  |  Presenter: Bruna Pellini

      • Abstract

      No abstract available for this presentation

    • +

      OA20.04 - Survival of Patients with Persistent N1 or N2 Disease After Induction Therapy for Stage IIIA-N2 Non-Small-Cell Lung Cancer  

      19:09 - 19:17  |  Presenter: Jorind Beqari

      • Abstract

      Loading...

    • +

      OA20.05 - Neoadjuvant Chemotherapy-alone vs Chemoradiation followed by Sleeve Resection for Locally Advanced Non-Small Cell Lung Cancer

      19:17 - 19:25  |  Presenter: Mark Jaradeh

      • Abstract

      Loading...

    • +

      OA20.06 - Discussant

      19:25 - 19:35  |  Presenter: Leah M. Backhus

      • Abstract

      No abstract available for this presentation

    • +

      OA20.07 - Live Discussion with Speakers

      19:35 - 19:45

      • Abstract

      No abstract available for this presentation

  • +

    MA16 - SCLC: New Targets, Biomarkers, and Systemic Therapies

    • 20:00 - 21:00
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Small Cell Lung Cancer/ NET
    • +

      MA16.01 - Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer

      20:00 - 20:05  |  Presenter: Vivek Subbiah

      • Abstract

      Loading...

    • +

      MA16.02 - Platinum-Doublets as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

      20:05 - 20:10  |  Presenter: Takashi Sato

      • Abstract

      Loading...

    • +

      MA16.03 - CRISPR Screen Reveals XPO1 as a Therapeutic Target Strongly Sensitizing to First and Second Line Therapy in Small Cell Lung Cancer

      20:10 - 20:15  |  Presenter: Alvaro Quintanal-Villalonga

      • Abstract

      Loading...

    • +

      MA16.04 - Discussant

      20:15 - 20:30  |  Presenter: Anish Thomas

      • Abstract

      No abstract available for this presentation

    • +

      MA16.06 - Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

      20:30 - 20:35  |  Presenter: Marina Chiara Garassino

      • Abstract

      Loading...

    • +

      MA16.07 - Prognostic Value of 18F-Fluorodeoxyglucose Uptake of Bone Marrow on PET/CT in Patients with Limited Disease Small Cell Lung Cancer

      20:35 - 20:40  |  Presenter: Merve Ayık Türk

      • Abstract

      Loading...

    • +

      MA16.08 - Discussant

      20:40 - 20:55  |  Presenter: Benjamin Drapkin

      • Abstract

      No abstract available for this presentation

  • +

    MA17 - Diagnostics and Pulmonology

    • 20:00 - 21:00
    • 9/13/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Staging/Pulmonary Medicine
    • +

      MA17.01 - Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors

      20:00 - 20:05  |  Presenter: Yi-Luen Shen

      • Abstract

      Loading...

    • +

      MA17.02 - Visualization of Patterns of Lymph Node Metastases in Non-Small Cell Lung Cancer Using Network Graph Analysis

      20:05 - 20:10  |  Presenter: Yukihiro Yoshida

      • Abstract

      Loading...

    • +

      MA17.03 - Discussant

      20:10 - 20:25  |  Presenter: Felix JF Herth

      • Abstract

      No abstract available for this presentation

    • +

      MA17.04 - Leave Paraesophageal Lymph Node or Not in a Lung Cancer Surgery? A Propensity-Matched Analysis Based on Ten-Year Population.

      20:25 - 20:30  |  Presenter: Xiaofei Wang

      • Abstract

      Loading...

    • +

      MA17.05 - Intrapulmonary Lymph Node (LN) Retrieval With a Novel Gross Dissection Method: A Prospective, Population-Based Cohort Study

      20:30 - 20:35  |  Presenter: Meredith Ray

      • Abstract

      Loading...

    • +

      MA17.06 - Nodal Upstaging Comparison of Open, Video-Assisted Thoracoscopic, and Robotic Lung Resections Form Non–Small Cell Lung Cancer

      20:35 - 20:40  |  Presenter: Ricardo Mingarini Terra

      • Abstract

      Loading...

    • +

      MA17.07 - Discussant

      20:40 - 20:55  |  Presenter: Young-Tae Kim

      • Abstract

      No abstract available for this presentation

  • +

    BEDG06 - IASLC Language Guide Idea Exchange on Adoption and Best Practices

    • 21:15 - 22:15
    • 9/13/2021
    • Location: Brain Exchange Lounge
    • Not for CME Credit
    • Type: Brain Exchange Discussion Groups
    • Track: N.A.
    • +

      BEDG06.01 - Join This Session to Learn about the New IASLC Language Guide

      21:15 - 22:15  |  Presenter: Jill Feldman, Kristin Ito

      • Abstract

      No abstract available for this presentation